<DOC>
	<DOCNO>NCT03043248</DOCNO>
	<brief_summary>This study comprise 2 cohort , cohort , study conduct open-label add-on study . The purpose study investigate pharmacokinetics substrate concomitant administration single dose P-glycoprotein substrate digoxin ( Cohort A ) CYP3A4 substrate midazolam ( Cohort B ) repeat administration TRK-700 healthy adult male .</brief_summary>
	<brief_title>TRK-700 Drug-Drug Interaction Study With Digoxin Midazolam</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Japanese healthy adult male . Subjects BMI least 18.0 less 30.0 screen examination examination admission . Subjects significant concomitant historical disease metabolism , liver , kidney , blood , lung , heart , digestive organ , urinary organ , nerve , psychiatric disease , accompany clinical symptom clinically significant disease , unsuitable participation study , opinion investigator . Subjects find investigator significant clinical abnormality screen examination , examination admission , examination day first administration Digoxin Midazolam .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TRK-700</keyword>
	<keyword>PK</keyword>
	<keyword>Digoxin</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Drug-Drug interaction</keyword>
	<keyword>P-glycoprotein</keyword>
	<keyword>CYP3A4</keyword>
	<keyword>MDR1</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>multidrug resistance 1</keyword>
</DOC>